OraSure Technologies, Inc.

372 articles with OraSure Technologies, Inc.

• InteliSwab® COVID-19 Rapid Test Validated to Detect the Omicron BA.2, BA.2.12.1, BA.3 and BA.5 Subvariants

  5/17/2022

  OraSure Technologies, Inc. announced that its InteliSwab® COVID-19 rapid tests detect the Omicron BA.2, BA.2.12.1, BA.3 and BA.5 subvariants with similar levels of detection to the original SARS-CoV-2 strain and other previous variants of concern, including Delta, Alpha, Beta, Gamma and Omicron BA.1.

• OraSure Reports 1Q22 Record Revenue of $67.7 Million; +16% Year-Over-Year With 21% Growth in Non-COVID Revenue

  5/10/2022

  OraSure Technologies, Inc. announced its financial results for the three months ended March 31, 2022.

• OraSure Technologies, Inc. 2022 First Quarter Earnings Conference Call Tuesday, May 10, 2022, 5:00 p.m. ET

  5/3/2022

  OraSure Technologies, Inc. (NASDAQ: OSUR) has scheduled its regular earnings conference call covering 2022 first quarter financial results and certain business developments for 5:00 pm ET (2:00 pm PT) on Tuesday, May 10, 2022.

• OraSure Technologies’ Subsidiary DNA Genotek Launches the First Device with De Novo Authorization from the FDA for the Preservation and Stabilization of Microbiome Samples

  4/7/2022

  OraSure Technologies, Inc. (NASDAQ: OSUR), a global leader in point-of-care and home diagnostic testing and sample collection technologies, announced today its OMNIgene®·GUT Dx (OMD-200) microbiome collection device, has been granted de novo authorization from the U.S. Food and Drug Administration (FDA) and the Company is commercially launching the device.

• OraSure Technologies’ Subsidiary Diversigen Launches Metatranscriptomic Sequencing and Analysis Services for Gut Microbiome Samples

  3/31/2022

  OraSure Technologies, Inc. announced that its’ Diversigen subsidiary has launched a new service to provide metatranscriptomic sequencing and analysis of gut microbiome samples.

• OraSure Director Nancy Gagliano Selected to Serve as Interim Chief Executive Officer; Brings Extensive Diagnostics and Healthcare Leadership Experience to Role

  3/22/2022

  OraSure Technologies, Inc., a leader in point-of-care and home diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services, announced that its Board of Directors has appointed Nancy Gagliano, MD to serve as interim Chief Executive Officer, effective April 1, 2022.

• OraSure Technologies Reports 4Q21 Revenue of $63.6 Million; InteliSwab® Production Scales Up

  2/23/2022

  OraSure Technologies, Inc., a leader in point-of-care and home diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services, announced its financial results for the three months ended December 31, 2021 and fiscal year 2021.

• OraSure Technologies, Inc. 2021 Fourth Quarter Earnings Conference Call Wednesday, February 23, 2022, 5:00 p.m. ET

  2/16/2022

  OraSure Technologies, Inc. (NASDAQ: OSUR) has scheduled its regular earnings conference call covering 2021 fourth quarter financial results and certain business developments for 5:00 pm ET (2:00 pm PT) on Wednesday, February 23, 2022.

• InteliSwab® COVID-19 Rapid Tests Receive U.S. FDA Authorization for Pediatric Use and Company Launches New InteliSwab® Connect Reporting App

  1/31/2022

  OraSure Technologies, Inc. (NASDAQ: OSUR), announced today that its InteliSwab® COVID-19 rapid tests have been authorized by the U.S. Food and Drug Administration (FDA) for use in children ages 2 to 14. InteliSwab® was previously authorized for use in adults and in children 15 to 17 when administered by an adult.

• OraSure Technologies, Inc. Expands HIV Oral Swab In-home Test into Europe

  1/25/2022

  OraSure Technologies, Inc., a global leader in point-of-care and home diagnostic testing and sample collection technologies, announced that it has launched its OraQuick® HIV Self-Test, an oral swab in-home test for HIV-1 and HIV-2, into Europe.

• InteliSwab® COVID-19 Rapid Tests Detect Omicron at Same Level as Other Variants

  1/13/2022

  OraSure Technologies, Inc., a global leader in point-of-care and home diagnostic testing and sample collection technologies, announced that its InteliSwab® COVID-19 rapid tests detect the Omicron variant as effectively as they detect the original SARS-CoV-2 strain and other previous variants of concern, including Delta, Alpha, Beta and Gamma.

• OraSure Technologies Announces Actions to Enhance Stockholder Value

  1/5/2022

  OraSure Technologies, Inc., a global leader in point-of-care and home diagnostic testing and sample collection technologies, announced preliminary Q4 2021 results, organizational changes, and a Board-level review of strategic alternatives to enhance stockholder value.

• OraSure Technologies Announces 2022 Annual Meeting Date

  12/14/2021

  OraSure Technologies, Inc. (NASDAQ: OSUR) today announced that its 2022 Annual Meeting of Stockholders is scheduled to be held at 10:00 a.m. EDT (7:00 a.m. PDT) on Tuesday, May 17, 2022.

• OraSure Technologies to Present at Upcoming Investor Conferences - Nov 19, 2021

  11/19/2021

  OraSure Technologies, Inc., a leader in point of care diagnostic tests, specimen collection devices, microbiome laboratory and analytical services, announced that Dr. Stephen S. Tang, President and CEO, will participate in a virtual fireside chat at the Stephens Annual Investment Conference on November 29, 2021 at 12:00 pm ET.

• OraSure Technologies Announces the Retirement of Jack E. Jerrett and Appointment of Agnieszka M. Gallagher as General Counsel, Chief Compliance Officer and Secretary

  11/9/2021

  OraSure Technologies, Inc., a global leader in point-of-care and home diagnostic testing and sample collection technologies, announced that after almost 21 years of service to the Company, Jack E. Jerrett is retiring as the Company’s Senior Vice President, General Counsel, Chief Compliance Officer and Secretary, effective as of December 31, 2021.

• OraSure Technologies Appoints Two New Members to the Board of Directors

  11/8/2021

  OraSure Technologies, Inc. announced today the appointment Nancy J. Gagliano, M.D. and Anne C. Whitaker to the Company’s Board of Directors, effective November 8, 2021. 

• OraSure Technologies Reports 3Q21 Revenue of $53.9 Million, Signs Three Major U.S. Government Contracts Positioning the Company for Significant InteliSwab™ Growth in FY22

  11/3/2021

  OraSure Technologies, Inc., a leader in point-of-care and home diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services, announced its financial results for the three months ended September 30, 2021.

• U.S. FDA Authorizes InteliSwab™ COVID-19 Rapid Tests for OTC Single-Use, At-Home Testing for Symptomatic People and Accepts Data for Delta Variant Detection

  11/2/2021

  OraSure Technologies, Inc., a global leader in point-of-care and home diagnostic testing and sample collection technologies, announced that the EUA for its InteliSwab™ COVID-19 rapid tests has been amended by the U.S. Food and Drug Administration to only require one test for individuals with symptoms of COVID-19.

• OraSure Technologies 2021 Third Quarter Earnings Conference Call Wednesday, November 3, 2021, 5:00 p.m. ET

  10/27/2021

  OraSure Technologies, Inc. (NASDAQ: OSUR) has scheduled its regular earnings conference call covering 2021 third quarter financial results and certain business developments for 5:00 pm ET (2:00 pm PT) on Wednesday, November 3, 2021.

• OraSure to Receive up to $13.6 Million from Biomedical Advanced Research Development Authority to Support InteliSwab™ COVID-19 Rapid Test 510(k) Clearance and CLIA Waiver

  9/23/2021

  OraSure Technologies, Inc. (NASDAQ: OSUR), announced today that the Biomedical Advanced Research Development Authority (BARDA), will provide up to $13.6 million in funding for the Company to obtain 510(k) clearance and Clinical Laboratory Improvement Amendments (CLIA) waiver for OraSure’s InteliSwab™ COVID-19 rapid test from the Food and Drug Administration (FDA).